Physician profile
David Koentop
NPI 1568842342
$291.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.25 · 2020: $60.18 · 2021: $175 · 2022: $13.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $56.12 | 2020-2021 | |
| Harmony Biosciences LLC | $42.00 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.67 | 2021 | |
| Amarin Pharma, INC. | $30.72 | 2020-2021 | |
| Vivus LLC | $15.80 | 2021 | |
| Shire North American Group INC | $14.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.90 | 2021 | |
| Orthogenrx INC. | $14.40 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.91 | 2021 | |
| Aytu Biopharma, INC. | $13.88 | 2019 | |
| Kaleo, INC. | $13.71 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.67 | 2022 | |
| Bioventus LLC | $13.23 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Koentop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.